Skip to main content

Table 3 Changes of the slopes* of the Gaucher-disease biomarkers

From: Bone events and evolution of biologic markers in Gaucher disease before and during treatment

 

Slope of variation (Unit)

P a

Biomarker

No./no.

Before ERT

No./no.

During ERT

No./no.

Full-dose ERT

 

Platelets (no splenectomy)b

9/70

190/mm3/y

38/480

7,035/mm3/y

33/220

10,231/mm3/y

<0.0001

Chitotriosidase

10/23

-11%/y

52/226

-17%/y

37/134

-14%/y

0.14

TRAP

7/14

-0.7%/y

36/214

-4%/y

24/109

-6%/y

0.78

ACE

9/33

0.1%/y

46/263

-5%/y

31/114

-4%/y

0.88

Ferritin

9/45

4%/y

47/338

-14%/y

37/166

-16%/y

<0.0001

  1. *Slopes were estimated by linear-mixed models before enzyme-replacement therapy (ERT), during ERT and for the patient subgroup receiving full-dose ERT. aComparison of slope values before vs during ERT. bOnly for nonsplenectomized patients. No./no. indicates number of patients with available data/total number of data available. ACE, angiotensin-converting enzyme; TRAP, tartrate-resistant acid phosphatase.